Determination of tigecycline in human cerebrospinal fluid by two-dimensional liquid chromatography and its clinical application
10.12206/j.issn.1006-0111.202003040
- VernacularTitle:二维液相色谱法测定脑脊液中替加环素浓度及其临床应用
- Author:
Caiyi CHENG
1
;
Dongmei DENG
1
;
Xianfeng WANG
1
;
Zheng YANG
1
;
Haiyan XING
1
Author Information
1. Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, China.
- Keywords:
tigecycline;
two-dimensional high-performance liquid chromatography;
intracranial infection;
drug monitoring;
cerebrospinal fluid
- From:
Journal of Pharmaceutical Practice
2020;38(6):543-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish a two-dimensional high-performance liquid chromatography method for the determination of tigecycline in human cerebrospinal fluid, which can be used for the drug monitoring in patients with intracranial infection. Methods The quantification was carried out by an external standard method. The first-dimension column was a Aston SNX5 phenyl chromatographic column (50 mm×4.6 mm, 5 μm) with ammonium phosphate (pH was adjusted with ammonium hydroxide to 7.5)-methanol (45∶55, V/V) as the mobile phase and the flow rate was 1.2 ml/min. The second-dimension chromatographic column was Aston SC5 C18 (275 mm×4.6 mm, 5 μm), with ammonium phosphate (pH was adjusted with ammonium hydroxide to 7.4)-ammonium phosphate (pH was adjusted with ammonium hydroxide to 3.0)- acetonitrile (30∶50∶20, V/V/V) as the mobile phase and the flow rate was 1.0 ml/min. The detection wavelength was 340 nm. The temperature was 40 ℃ and the injection volume was 200 μl. Results The calibration curve of tigecycline showed good linearity from 64.5 to 1 290.0 ng/ml in human cerebrospinal fluid (r=0.999 8). The RSD of intra and inter-day precision were less than 5.0% with the detection accuracy of 98.80%−106.51%. Conclusion This method is simple, quick, accurate, specific and sensitive. It meets the requirements of tigecycline determination in clinical human cerebrospinal fluid, which offers the individualized therapeutic assurance for patients with intracranial infection.
